抗血小板治疗在血管内治疗缺血性脑血管病中的应用

doi:10.3969/j.issn.1673-5765.2020.02.019

摘要/Abstract

摘要：

血管内治疗能显著降低缺血性脑血管病的致残、病死及卒中复发率。随着神经介入技术和材料以及患者筛选策略的进步，缺血性卒中患者应用血管内治疗也日益增加。抗血小板治疗作为缺血性卒中预防和治疗的重要手段，是血管内治疗中的重要一环，阿司匹林、氯吡格雷等是基石性抗血小板药物，但具体的用药方案尚不统一。本文回顾和总结了国内外指南针对缺血性脑血管病行血管内治疗患者的抗血小板策略建议，以及重要血管内治疗研究中采用的抗血小板治疗方案，以期为神经介入医师行血管内治疗时抗血小板药物的应用提供参考。

文章导读： 抗血小板治疗在缺血性脑血管病血管内治疗中占有重要位置，在缺乏直接证据的情况下，借鉴指南及重要研究中的治疗策略有利于辅助临床实践。

关键词: 血管内治疗; 缺血性卒中; 抗血小板治疗

Abstract:

Endovascular treatment (EVT) can significantly reduce the morbidity, mortality and recurrence of ischemic cerebrovascular disease. With the development of EVT technology, materials, and patients screening strategy, EVT is increasely used in patients with ischemic stroke. As an important prevention and treatment regimen of ischemic stroke, antiplatelet therapy is an important part of EVT. Aspirin and clopidogrel are cornerstone antiplatelet agents, however, the specific antiplatelet regimen has not yet been unified. This article reviewed the recommendations of several guidelines for antiplatelet strategies for EVT patients, as well as the antiplatelet regimen in important EVT studies, to provide reference for neuointerventionists.

Key words: Endovascular treatment; Ischemic stroke; Antiplatelet therapy

马高亭，缪中荣. 抗血小板治疗在血管内治疗缺血性脑血管病中的应用[J]. 中国卒中杂志, 2020, 15(02): 202-208.

MA Gao-Ting, MIAO Zhong-Rong. Antiplatelet Therapy in Endovascular Treatment for Ischemic Cerebrovascular Disease[J]. Chinese Journal of Stroke, 2020, 15(02): 202-208.

参考文献

[1] 《中国脑卒中防治报告2018》编写组. 我国脑卒中防

治仍面临巨大挑战——《中国脑卒中防治报告2018》

概要[J]. 中国循环杂志，2019，34（2）：105-119.

[2] LEES K R，BLUHMKI E，VON KUMMER R，et

al. Time to treatment with intravenous alteplase

and outcome in stroke：an updated pooled analysis

of ECASS，ATLANTIS，NINDS，and EPITHET

trials[J]. Lancet，2010，375（9727）：1695-1703.

[3] EMBERSON J，LEES K R，LYDEN P，et al. Effect

of treatment delay，age，and stroke severity on the

effects of intravenous thrombolysis with alteplase for

acute ischaemic stroke：a meta-analysis of individual

patient data from randomised trials[J]. Lancet，2014，

384（9958）：1929-1935.

[4] BHATIA R，HILL M D，SHOBHA N，et al. Low

rates of acute recanalization with intravenous

recombinant tissue plasminogen activator in

ischemic stroke：real-world experience and a call for

action[J]. Stroke，2010，41（10）：2254-2258.

[5] BERKHEMER O A，FRANSEN P S，BEUMER D，et al. A randomized trial of intraarterial treatment

for acute ischemic stroke[J]. N Engl J Med，2015，372

（1）：11-20.

[6] GOYAL M，DEMCHUK A M，MENON B K，et

al. Randomized assessment of rapid endovascular

treatment of ischemic stroke[J]. N Engl J Med，2015，

372（11）：1019-1030.

[7] JOVIN T G，CHAMORRO A，COBO E，et al.

Thrombectomy within 8 hours after symptom onset

in ischemic stroke[J]. N Engl J Med，2015，372（24）：

2296-2306.

[8] SAVER J L，GOYAL M，BONAFE A，et al. Stentretriever

thrombectomy after intravenous t-PA vs .

t-PA alone in stroke[J]. N Engl J Med，2015，372

（24）：2285-2295.

[9] CAMPBELL B C，MITCHELL P J，KLEINIG T J，

et al. Endovascular therapy for ischemic stroke with

perfusion-imaging selection[J]. N Engl J Med，2015，

372（11）：1009-1018.

[10] 中华医学会神经病学分会，中华医学会神经病学分

会脑血管病学组，中华医学会神经病学分会神经血

管介入协作组. 中国急性缺血性脑卒中早期血管内介

入诊疗指南2018[J]. 中华神经科杂志，2018，51（9）：

683-691.

[11] NOGUEIRA R G，JADHAV A P，HAUSSEN D C，

et al. Thrombectomy 6 to 24 hours after stroke with

a mismatch between deficit and infarct[J]. N Engl J

Med，2018，378（1）：11-21.

[12] ALBERS G W，MARKS M P，KEMP S，et al.

Thrombectomy for stroke at 6 to 16 hours with

selection by perfusion imaging[J]. N Engl J Med，

2018，378（8）：708-718.

[13] NAHAB F，KASS-HOUT T，SHALTONI H M.

Periprocedural antithrombotic strategies in acute

ischemic stroke interventional therapy[J]. Neurology，

2012，79（13 Suppl 1）：S174-181.

[14] 中华预防医学会卒中预防与控制专业委员会介入学

组. 缺血性脑血管病介入治疗抗血小板策略中国专

家共识[J]. 中华医学杂志，2015，95（11）：803-809.

[15] 国家卫生健康委脑卒中防治工程委员会，中华医学

会神经外科学分会神经介入学组，中华医学会放射

学分会介入学组，等. 急性大血管闭塞性缺血性卒中

血管内治疗中国专家共识（2019年修订版）[J]. 中华

神经外科杂志，2019，35（9）：868-879.

[16] 中国卒中学会重症脑血管病分会专家撰写组. 急性

缺血性脑卒中血管内治疗术后监护与管理中国专家

共识[J]. 中华医学杂志，2017，97（3）：162-172.

[17] 中国卒中学会，中国卒中学会神经介入分会，中华预

防医学会卒中预防与控制专业委员会介入学组. 急性

缺血性卒中血管内治疗中国指南2018[J]. 中国卒中

杂志，2018，13（7）：706-729.

[18] NAYLOR A R，RICCO J B，DE BORST G J，et al.

Management of atherosclerotic carotid and vertebral

artery disease：2017 clinical practice guidelines of

the European Society for Vascular Surgery（ESVS）

[J]. Eur J Vasc Endovasc Surg，2018，55（1）：3-81.

[19] BROEG-MORVAY A，MORDASINI P，SLEZAK

A，et al. Does antiplatelet therapy during bridging

thrombolysis increase rates of intracerebral

hemorrhage in stroke patients?[J/OL]. PLoS One，

2017，12（1）：e0170045[2019-12-12]. https：//doi.

org/10.1371/journal.pone.0170045.

[20] JEONG H G，KIM B J，YANG M H，et al. Stroke

outcomes with use of antithrombotics within 24

hours after recanalization treatment[J]. Neurology，

2016，87（10）：996-1002.

[21] ALBERS G W，LANSBERG M G，KEMP S，et

al. A multicenter randomized controlled trial of

endovascular therapy following imaging evaluation

for ischemic stroke（DEFUSE 3）[J]. Int J Stroke，

2017，12（8）：896-905.

[22] MULDER M J，BERKHEMER O A，FRANSEN P

S，et al. Does prior antiplatelet treatment improve

functional outcome after intra-arterial treatment for

acute ischemic stroke?[J]. Int J Stroke，2017，12（4）：

368-376.

[23] PANDHI A，TSIVGOULIS G，KRISHNAN R，et

al. Antiplatelet pretreatment and outcomes following

mechanical thrombectomy for emergent large vessel

occlusion strokes[J]. J Neurointerv Surg，2018，10

（9）：828-833.

[24] JIA B，FENG L，LIEBESKIND D S，et al.

Mechanical thrombectomy and rescue therapy for

intracranial large artery occlusion with underlying

atherosclerosis[J]. J Neurointerv Surg，2018，10（8）：

746-750.

[25] ZHAO W，CHE R，SHANG S，et al. Low-dose

tirofiban improves functional outcome in acute

ischemic stroke patients treated with endovascular

thrombectomy[J]. Stroke，2017，48（12）：3289-3294.

[26] DELGADO F，OTEROS R，JIMENEZ-GOMEZ

E，et al. Half bolus dose of intravenous abciximab

is safe and effective in the setting of acute stroke

endovascular treatment[J]. J Neurointerv Surg，2019，

11（2）：147-152.

[27] RANGEL-CASTILLA L，RAJAH G B，SHAKIR

H J，et al. Management of acute ischemic stroke

due to tandem occlusion：should endovascular

recanalization of the extracranial or intracranial

occlusive lesion be done first?[J/OL]. Neurosurg

Focus，2017，42（4）：E16[2019-12-12]. https：//doi.

org/10.3171/2017.1.FOCUS16500.

[28] BROTT T G，HOBSON R W 2nd，HOWARD G，et

al. Stenting versus endarterectomy for treatment of

carotid-artery stenosis[J]. N Engl J Med，2010，363

（1）：11-23.

[29] BROTT T G，HOWARD G，ROUBIN G S，et al.

Long-term results of stenting versus endarterectomy

for carotid-artery stenosis[J]. N Engl J Med，2016，

374（11）：1021-1031.

[30] MCKEVITT F M，RANDALL M S，CLEVELAND

T J，et al. The benefits of combined antiplatelet

treatment in carotid artery stenting[J]. Eur J Vasc

Endovasc Surg，2005，29（5）：522-527.

[31] PEETERS W S M，VAN HAELST S T，DEN

RUIJTER H M，et al. Lack of evidence for dual

antiplatelet therapy after endovascular arterial

procedures：a meta-analysis[J]. Eur J Vasc Endovasc

Surg，2016，52（2）：253-262.

[32] CHIMOWITZ M I，LYNN M J，DERDEYN C P，et

al. Stenting versus aggressive medical therapy for

intracranial arterial stenosis[J]. N Engl J Med，2011，

365（11）：993-1003.

[33] DERDEYN C P，CHIMOWITZ M I，LYNN M J，et

al. Aggressive medical treatment with or without

stenting in high-risk patients with intracranial

artery stenosis（SAMMPRIS）：the final results of a

randomised trial[J]. Lancet，2014，383（9914）：333-

341.

[34] DERDEYN C P，FIORELLA D，LYNN M J，et al.

Nonprocedural symptomatic infarction and in-stent

restenosis after intracranial angioplasty and stenting

in the SAMMPRIS trial（Stenting and Aggressive

Medical Management for the Prevention of Recurrent

Stroke in Intracranial Stenosis）[J]. Stroke，2017，48

（6）：1501-1506.

[35] HASSAN A E，ZACHARATOS H，VAZQUEZ

G，et al. Low risk of intracranial and systemic

hemorrhages in patients on dual antiplatelet

treatment beyond 1 month following

neuroendovascular angioplasty and/or stent

placement[J]. J Neuroimaging，2012，22（1）：67-73.

[36] CHEN X，HUANG Q，HONG B，et al. Drug-eluting

stent for the treatment of symptomatic vertebral

origin stenosis：long-term results[J]. J Clin Neurosci，

2011，18（1）：47-51.

[37] VAJDA Z，AGUILAR M，GÖHRINGER T，et al.

Treatment of intracranial atherosclerotic disease

with a balloon-expandable paclitaxel eluting stent：

procedural safety，efficacy and mid-term patency[J].

Clin Neuroradiol，2012，22(3)：227-233.